Cyclosporine minimization and cost reduction in renal transplant recipients recieving a C2-monitored, cyclosporin-based quadruple immunosuppressive regimen

Karen L. Hardinger, Mark A. Schnitzler, Matthew J. Koch, Decha Enkvetchakul, Niraj M Desai, Martin Jendrisak, Jeffrey A. Lowell, Brent Miller, Surendra Shenoy, Daniel Brennan

Research output: Contribution to journalArticle

Abstract

Background. Targeting 2-hr postdose cyclosporine (C2) levels to 1,000 to 1,700 mg/dL during the first 6 months after renal transplantation is recommended for triple immunosuppressive regimens. This trial determines whether lower C2 levels could be targeted safely in de novo kidney transplant recipients under a quadruple regimen compared with a similar cohort monitored with trough (CO) levels. Methods. This single-center, sequential, cohort-designed trial included patients who received Thymoglobulin, corticosteroids, an antimetabolite, and cyclosporine monitored by C2 (n=50) or C0 (n=50). Cyclosporine was tapered to maintain the C2 between 1,000 and 1,200 ng/mL months O to 3 and between 600 and 1,000 ng/mL thereafter and C0 between 250 and 350 ng/mL months 0 to 3 and between 100 and 250 ng/mL thereafter. Results. Baseline patient and donor characteristics were similar. There were no differences in graft survival (100% C2 vs. 100% C0), acute rejection (4% C2 vs. 6% C0), allograft function, or adverse events at 6 months. C2 levels were lower than the suggested guidelines throughout the study (33% lower at 1 month and 48% lower at 6 months). Lower cyclosporine doses were achieved in the C2 arm compared with the C0 arm by 1 month and were sustained throughout the trial, which translated into an average cyclosporine cost savings of $773 in the C2 arm during the 6-month period (P

Original languageEnglish (US)
Pages (from-to)1198-1203
Number of pages6
JournalTransplantation
Volume78
Issue number8
DOIs
StatePublished - Oct 27 2004
Externally publishedYes

Fingerprint

Immunosuppressive Agents
Cyclosporine
Kidney
Costs and Cost Analysis
Arm
Antimetabolites
Cost Savings
Graft Survival
Carbon Monoxide
Kidney Transplantation
Allografts
Adrenal Cortex Hormones
Transplant Recipients
Tissue Donors
Guidelines

Keywords

  • Cyclosporine
  • Drug monitoring
  • Outcomes
  • Thymoglobulin

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Cyclosporine minimization and cost reduction in renal transplant recipients recieving a C2-monitored, cyclosporin-based quadruple immunosuppressive regimen. / Hardinger, Karen L.; Schnitzler, Mark A.; Koch, Matthew J.; Enkvetchakul, Decha; Desai, Niraj M; Jendrisak, Martin; Lowell, Jeffrey A.; Miller, Brent; Shenoy, Surendra; Brennan, Daniel.

In: Transplantation, Vol. 78, No. 8, 27.10.2004, p. 1198-1203.

Research output: Contribution to journalArticle

Hardinger, Karen L. ; Schnitzler, Mark A. ; Koch, Matthew J. ; Enkvetchakul, Decha ; Desai, Niraj M ; Jendrisak, Martin ; Lowell, Jeffrey A. ; Miller, Brent ; Shenoy, Surendra ; Brennan, Daniel. / Cyclosporine minimization and cost reduction in renal transplant recipients recieving a C2-monitored, cyclosporin-based quadruple immunosuppressive regimen. In: Transplantation. 2004 ; Vol. 78, No. 8. pp. 1198-1203.
@article{f8fb08f0f18b4c47bdcc5e4af4acd2b0,
title = "Cyclosporine minimization and cost reduction in renal transplant recipients recieving a C2-monitored, cyclosporin-based quadruple immunosuppressive regimen",
abstract = "Background. Targeting 2-hr postdose cyclosporine (C2) levels to 1,000 to 1,700 mg/dL during the first 6 months after renal transplantation is recommended for triple immunosuppressive regimens. This trial determines whether lower C2 levels could be targeted safely in de novo kidney transplant recipients under a quadruple regimen compared with a similar cohort monitored with trough (CO) levels. Methods. This single-center, sequential, cohort-designed trial included patients who received Thymoglobulin, corticosteroids, an antimetabolite, and cyclosporine monitored by C2 (n=50) or C0 (n=50). Cyclosporine was tapered to maintain the C2 between 1,000 and 1,200 ng/mL months O to 3 and between 600 and 1,000 ng/mL thereafter and C0 between 250 and 350 ng/mL months 0 to 3 and between 100 and 250 ng/mL thereafter. Results. Baseline patient and donor characteristics were similar. There were no differences in graft survival (100{\%} C2 vs. 100{\%} C0), acute rejection (4{\%} C2 vs. 6{\%} C0), allograft function, or adverse events at 6 months. C2 levels were lower than the suggested guidelines throughout the study (33{\%} lower at 1 month and 48{\%} lower at 6 months). Lower cyclosporine doses were achieved in the C2 arm compared with the C0 arm by 1 month and were sustained throughout the trial, which translated into an average cyclosporine cost savings of $773 in the C2 arm during the 6-month period (P",
keywords = "Cyclosporine, Drug monitoring, Outcomes, Thymoglobulin",
author = "Hardinger, {Karen L.} and Schnitzler, {Mark A.} and Koch, {Matthew J.} and Decha Enkvetchakul and Desai, {Niraj M} and Martin Jendrisak and Lowell, {Jeffrey A.} and Brent Miller and Surendra Shenoy and Daniel Brennan",
year = "2004",
month = "10",
day = "27",
doi = "10.1097/01.TP.0000137423.01887.7D",
language = "English (US)",
volume = "78",
pages = "1198--1203",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Cyclosporine minimization and cost reduction in renal transplant recipients recieving a C2-monitored, cyclosporin-based quadruple immunosuppressive regimen

AU - Hardinger, Karen L.

AU - Schnitzler, Mark A.

AU - Koch, Matthew J.

AU - Enkvetchakul, Decha

AU - Desai, Niraj M

AU - Jendrisak, Martin

AU - Lowell, Jeffrey A.

AU - Miller, Brent

AU - Shenoy, Surendra

AU - Brennan, Daniel

PY - 2004/10/27

Y1 - 2004/10/27

N2 - Background. Targeting 2-hr postdose cyclosporine (C2) levels to 1,000 to 1,700 mg/dL during the first 6 months after renal transplantation is recommended for triple immunosuppressive regimens. This trial determines whether lower C2 levels could be targeted safely in de novo kidney transplant recipients under a quadruple regimen compared with a similar cohort monitored with trough (CO) levels. Methods. This single-center, sequential, cohort-designed trial included patients who received Thymoglobulin, corticosteroids, an antimetabolite, and cyclosporine monitored by C2 (n=50) or C0 (n=50). Cyclosporine was tapered to maintain the C2 between 1,000 and 1,200 ng/mL months O to 3 and between 600 and 1,000 ng/mL thereafter and C0 between 250 and 350 ng/mL months 0 to 3 and between 100 and 250 ng/mL thereafter. Results. Baseline patient and donor characteristics were similar. There were no differences in graft survival (100% C2 vs. 100% C0), acute rejection (4% C2 vs. 6% C0), allograft function, or adverse events at 6 months. C2 levels were lower than the suggested guidelines throughout the study (33% lower at 1 month and 48% lower at 6 months). Lower cyclosporine doses were achieved in the C2 arm compared with the C0 arm by 1 month and were sustained throughout the trial, which translated into an average cyclosporine cost savings of $773 in the C2 arm during the 6-month period (P

AB - Background. Targeting 2-hr postdose cyclosporine (C2) levels to 1,000 to 1,700 mg/dL during the first 6 months after renal transplantation is recommended for triple immunosuppressive regimens. This trial determines whether lower C2 levels could be targeted safely in de novo kidney transplant recipients under a quadruple regimen compared with a similar cohort monitored with trough (CO) levels. Methods. This single-center, sequential, cohort-designed trial included patients who received Thymoglobulin, corticosteroids, an antimetabolite, and cyclosporine monitored by C2 (n=50) or C0 (n=50). Cyclosporine was tapered to maintain the C2 between 1,000 and 1,200 ng/mL months O to 3 and between 600 and 1,000 ng/mL thereafter and C0 between 250 and 350 ng/mL months 0 to 3 and between 100 and 250 ng/mL thereafter. Results. Baseline patient and donor characteristics were similar. There were no differences in graft survival (100% C2 vs. 100% C0), acute rejection (4% C2 vs. 6% C0), allograft function, or adverse events at 6 months. C2 levels were lower than the suggested guidelines throughout the study (33% lower at 1 month and 48% lower at 6 months). Lower cyclosporine doses were achieved in the C2 arm compared with the C0 arm by 1 month and were sustained throughout the trial, which translated into an average cyclosporine cost savings of $773 in the C2 arm during the 6-month period (P

KW - Cyclosporine

KW - Drug monitoring

KW - Outcomes

KW - Thymoglobulin

UR - http://www.scopus.com/inward/record.url?scp=20844452706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844452706&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000137423.01887.7D

DO - 10.1097/01.TP.0000137423.01887.7D

M3 - Article

C2 - 15502720

AN - SCOPUS:20844452706

VL - 78

SP - 1198

EP - 1203

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -